Segers Vincent F M, Lee Richard T
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Partners Research Facility, 65 Landsdowne Street, Cambridge, Massachusetts 02139, USA.
Nature. 2008 Feb 21;451(7181):937-42. doi: 10.1038/nature06800.
Heart failure is the leading cause of death worldwide, and current therapies only delay progression of the disease. Laboratory experiments and recent clinical trials suggest that cell-based therapies can improve cardiac function, and the implications of this for cardiac regeneration are causing great excitement. Bone-marrow-derived progenitor cells and other progenitor cells can differentiate into vascular cell types, restoring blood flow. More recently, resident cardiac stem cells have been shown to differentiate into multiple cell types present in the heart, including cardiac muscle cells, indicating that the heart is not terminally differentiated. These new findings have stimulated optimism that the progression of heart failure can be prevented or even reversed with cell-based therapy.
心力衰竭是全球范围内主要的死亡原因,目前的治疗方法只能延缓疾病的进展。实验室实验和近期的临床试验表明,基于细胞的治疗方法可以改善心脏功能,这对于心脏再生的意义引发了极大的关注。骨髓来源的祖细胞和其他祖细胞可以分化为血管细胞类型,恢复血流。最近,心脏驻留干细胞已被证明可以分化为心脏中存在的多种细胞类型,包括心肌细胞,这表明心脏并非终末分化。这些新发现激发了人们的乐观情绪,即基于细胞的治疗可以预防甚至逆转心力衰竭的进展。